Haemonetics Corporation (HAE) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.

Total Revenue Chart for Haemonetics Corporation

Haemonetics Corporation (HAE) revenue for FY2026 was USD 1.3B, a -2.0% change from FY2025. Haemonetics Corporation's revenue grew from USD 157.3M in 1991 to USD 1.3B in 2026 (748.1% over 35 years). Earnings per share grew from USD 0.36 in 2000 to USD 3.31 in 2025 (829.2%). Revenue compound annual growth rate: 5-year CAGR of 8.9%, 10-year CAGR of 3.9%, 20-year CAGR of 6.0%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$4.71B
Implied Share Price
$103.52
Enterprise Value
$5.81B
Revenue (TTM)
$1.35B
EBITDA
$358.79M
Profit Margin
7.12%
Trailing P/E
50.01
Forward P/E
20.33
Price/Book (MRQ)
5.81
Price/Sales (TTM)
3.48
EV/EBITDA
9.36
EV/Revenue
4.30
Dividend Yield
—
Book Value
$18.41
Free Cash Flow (FY2026)
$260.44M
Free Cash Flow Yield
5.53%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.